D. Blum, C. Hertler, R. Oberholzer, S. Wolf-Linder, M. Joerger, C. Driessen, F. Strasser
{"title":"来那度胺治疗癌症恶病质：一项抗恶病质抗癌药物的随机试验","authors":"D. Blum, C. Hertler, R. Oberholzer, S. Wolf-Linder, M. Joerger, C. Driessen, F. Strasser","doi":"10.1002/rco2.54","DOIUrl":null,"url":null,"abstract":"Cancer cachexia (CC) impacts quality of life, physical function, anticancer treatment response, and survival. Inflammation is a prominent pathomechanism of CC. This small‐scale study sets out to investigate the immunomodulatory drug lenalidomide in inflammatory CC in a randomized, double‐blind, placebo‐controlled trial.","PeriodicalId":73544,"journal":{"name":"JCSM rapid communications","volume":"5 1","pages":"68 - 76"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti‐cachexia\",\"authors\":\"D. Blum, C. Hertler, R. Oberholzer, S. Wolf-Linder, M. Joerger, C. Driessen, F. Strasser\",\"doi\":\"10.1002/rco2.54\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer cachexia (CC) impacts quality of life, physical function, anticancer treatment response, and survival. Inflammation is a prominent pathomechanism of CC. This small‐scale study sets out to investigate the immunomodulatory drug lenalidomide in inflammatory CC in a randomized, double‐blind, placebo‐controlled trial.\",\"PeriodicalId\":73544,\"journal\":{\"name\":\"JCSM rapid communications\",\"volume\":\"5 1\",\"pages\":\"68 - 76\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCSM rapid communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rco2.54\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCSM rapid communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rco2.54","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti‐cachexia
Cancer cachexia (CC) impacts quality of life, physical function, anticancer treatment response, and survival. Inflammation is a prominent pathomechanism of CC. This small‐scale study sets out to investigate the immunomodulatory drug lenalidomide in inflammatory CC in a randomized, double‐blind, placebo‐controlled trial.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
